Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

US FDA Mum On Whether Woodcock Would Stick Around Long-Term For Califf

Executive Summary

Woodcock’s willingness to stay on at US FDA for more than a transitional period after Robert Califf’s expected confirmation as commissioner may depend on exactly the type of authority and tasks he’d be willing to delegate to her. Plus, some other agency personnel updates.

You may also be interested in...



Dr. Califf Returns To US FDA: What To Do First?

Acting commissioner Janet Woodcock will remain at the agency and become principal deputy commissioner when Califf arrives.

Dr. Califf Returns To US FDA: What To Do First?

Acting commissioner Janet Woodcock will remain at the agency and become principal deputy commissioner when Califf arrives.

FDA Creates Division To Support First Amendment Policy Development, Oversee Advertising Research

Multiple unfavorable court decisions have forced the agency to adjust its advertising enforcement strategies.

Related Content

Topics

Latest News
UsernamePublicRestriction

Register

PS145343

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel